Jazz Pharmaceuticals (J7Z) Financial Statements
Jazz Pharmaceuticals Financial Overview
Jazz Pharmaceuticals's market cap is currently $12.51B. The company's EPS TTM is $15.20; its P/E ratio is 14.21; Jazz Pharmaceuticals is estimated to report earnings on November 2, 2026, and the estimated EPS forecast is $-3.61. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 4.27B | $ 4.07B | $ 3.83B | $ 3.66B | $ 3.09B |
| Gross Profit | $ 3.76B | $ 3.62B | $ 3.40B | $ 3.12B | $ 2.65B |
| Operating Income | $ 224.42M | $ 716.63M | $ 578.58M | $ -65.53M | $ 170.28M |
| EBITDA | $ 262.76M | $ 1.52B | $ 1.45B | $ 1.47B | $ 1.03B |
| Net Income | $ -356.15M | $ 560.12M | $ 414.83M | $ -224.06M | $ -328.95M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.44B | $ 2.99B | $ 1.63B | $ 881.48M | $ 591.45M |
| Total Assets | $ 11.66B | $ 12.01B | $ 11.39B | $ 10.84B | $ 12.30B |
| Total Debt | $ 5.42B | $ 6.16B | $ 5.79B | $ 5.81B | $ 6.15B |
| Net Debt | $ 4.03B | $ 3.75B | $ 4.29B | $ 4.93B | $ 5.56B |
| Total Liabilities | $ 7.34B | $ 7.92B | $ 7.66B | $ 7.75B | $ 8.33B |
| Stockholders' Equity | $ 4.32B | $ 4.09B | $ 3.74B | $ 3.09B | $ 3.97B |
| Cash Flow | |||||
| Free Cash Flow | $ 1.15B | $ 1.35B | $ 1.07B | $ 773.78M | $ 732.98M |
| Operating Cash Flow | $ 1.36B | $ 1.40B | $ 1.09B | $ 1.27B | $ 778.51M |
| Investing Cash Flow | $ -1.51B | $ -508.19M | $ -163.06M | $ -446.23M | $ -5.21B |
| Financing Cash Flow | $ -873.38M | $ 20.52M | $ -305.25M | $ -529.49M | $ 3.97B |
Currency in USD